[MVA-vaccine in primovaccination against smallpox after the age of three (author's transl)].
These are the results of 417 primary vaccinations against smallpox with MVA, an attenuated vaccine. All of the patients were over three years old. In Europe, this group has an increased risk of postvaccinal encephalitis. The intracutaneous inoculation produced a light local infiltration and only 11.7% showed a light generalized reaction. In order to attain a reliable immunity, a second inoculation was performed one week later, epicutaneously with Elstree-vaccine. The local reaction was in general that of a normal revaccination, and 79.4% of our patients had neither fever nor general symptoms. Among the others no one became seriously ill. We did not observe any complications specific for a smallpox vaccination. In comparison to the other vaccination methods currently used, the MVA "Two-step"-vaccination is probably the safest. Its risk of a postvaccinal encephalitis is supposed to be lower according to animal experiments and theoretical considerations. This hypothesis has been confirmed meanwhile by the results of several thousand vaccinations in the already mentioned age-group.
D000328:Adult; D006801:Humans; D007109:Immunity; D007271:Injections, Intradermal; D012899:Smallpox / Q000276:immunology / Q000517:prevention & control*; D012900:Smallpox Vaccine; D014611:Vaccination / Q000009:adverse effects / Q000379:methods; D014613:Vaccines, Attenuated
D012900:Smallpox Vaccine; D014613:Vaccines, Attenuated
MVA-Stufenimpfung bei Pockenschutz-Erstimpfungen nach dem dritten Lebensjahr.